Systemic Inflammatory and Autoimmune Diseases (SIADs) and hematological malignancies have been associated with individual patients and in larger case series for at least 25 years. These manifestations involve both lymphoid and myeloid neoplasms. Among them, autoimmune cytopenia is well-described, but other systemic autoimmune phenomena such as vasculitis or connective tissue neutrophilic dermatosis are less investigated. Diagnostic of these SIADs may be challenging, and some treatments such as targeting IL-2-inducible T cell kinase (ITK) or using checkpoint inhibitors (CPI) may also participate in these manifestations. SIAD management is often complicated in the context of hematological malignancies. Finally, somatic mutations can also explain some associations of hematological malignancies with SIADs, such as the recently described UBA1 mutation in VEXAS syndrome.
The goal of this Research Topic is to provide Frontiers' readers with comprehensive data about these complex diseases including recent advances in this area.
This Research Topic aims to publish all types of articles, including original research articles, review articles as well as short communications about SIADs and their association with hematological malignancies (myeloid, lymphoid, myeloproliferative) or in relation to their treatments, including Hematopoietic Stem Cell Transplantation (HSCT) or use of CAR-T cells. We also invite colleagues who want to publish articles about VEXAS syndrome.
Keywords:
SIAD, autoimmune hemolytic anemia, immune thrombocytopenia, chronic lymphocytic leukemia, lymphoma, myelodysplastic syndrome, chronic myelomonocytic leukemia, myeloproliferative neoplasms, systemic lupus erythematosus, rheumatoid arthritis, vasculitis, neutrophilic dermatosis, connective tissue disease, VEXAS, UBA1
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Systemic Inflammatory and Autoimmune Diseases (SIADs) and hematological malignancies have been associated with individual patients and in larger case series for at least 25 years. These manifestations involve both lymphoid and myeloid neoplasms. Among them, autoimmune cytopenia is well-described, but other systemic autoimmune phenomena such as vasculitis or connective tissue neutrophilic dermatosis are less investigated. Diagnostic of these SIADs may be challenging, and some treatments such as targeting IL-2-inducible T cell kinase (ITK) or using checkpoint inhibitors (CPI) may also participate in these manifestations. SIAD management is often complicated in the context of hematological malignancies. Finally, somatic mutations can also explain some associations of hematological malignancies with SIADs, such as the recently described UBA1 mutation in VEXAS syndrome.
The goal of this Research Topic is to provide Frontiers' readers with comprehensive data about these complex diseases including recent advances in this area.
This Research Topic aims to publish all types of articles, including original research articles, review articles as well as short communications about SIADs and their association with hematological malignancies (myeloid, lymphoid, myeloproliferative) or in relation to their treatments, including Hematopoietic Stem Cell Transplantation (HSCT) or use of CAR-T cells. We also invite colleagues who want to publish articles about VEXAS syndrome.
![]()
Keywords:
SIAD, autoimmune hemolytic anemia, immune thrombocytopenia, chronic lymphocytic leukemia, lymphoma, myelodysplastic syndrome, chronic myelomonocytic leukemia, myeloproliferative neoplasms, systemic lupus erythematosus, rheumatoid arthritis, vasculitis, neutrophilic dermatosis, connective tissue disease, VEXAS, UBA1
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
